Monoclonal antibodyFDA-approvedSecond-line
Panitumumab
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Colorectal Cancer— Wild-type KRAS
Efficacy
In clinical trials, patients with KRAS wild-type tumors treated with panitumumab had a median overall survival of approximately 19 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pancreatic Cancer Trial Examines Chemotherapy with or without Panitumumab | Pancreatic Cancer | phase-3 | — | Source → |
| Panitumumab-IRDye800 Trial for Pancreatic Cancer Patients Undergoing Surgery | Pancreatic Cancer | phase-1 | — | Source → |
| Early Magnesium Supplementation Helps Manage Hypomagnesemia in Colorectal Cancer Patients | Colorectal Cancer | observational | The incidence of grade 3 or higher hypomagnesemia was significantly lower in the post-protocol group than in the pre-protocol group (3.3% vs. 30.0%). | Source → |
| New Cancer Treatment Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | The overall response rates were 30.2% for sotorasib 960 mg-panitumumab, 7.5% for sotorasib 240 mg-panitumumab, and 1.9% for investigator's choice. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.